An Academic Perspective to Making First-Line Treatment Decisions for EGFR-mutated Metastatic NSCLC

An expert discusses treatment goals for patients with EGFR-mutated advanced/metastatic NSCLC, how to approach combination therapy with high-risk patients, and how recent data has influenced their practice.

EP: 1.A 55-Year-Old Man with EGFR-mutated Advanced/Metastatic NSCLC

EP: 2.Recent Advances in First-Line Combination Therapy for EGFR-mutated Metastatic NSCLC: Exploring Amivantamab + Lazertinib and Osimertinib-Based Regimens

Now Viewing

EP: 3.An Academic Perspective to Making First-Line Treatment Decisions for EGFR-mutated Metastatic NSCLC

EP: 4.First-Line Treatment Approaches for EGFR-mutated Metastatic NSCLC: Updates from MARIPOSA High-Risk Analyses

EP: 5.Management of Adverse Events with First-Line Combination Therapies for EGFR-mutated NSCLC

EP: 6.Considerations for Treatment of Advanced/Metastatic EGFR-mutated NSCLC

• What are your treatment goals for patients with EGFR-mutated A/M NSCLC?
• How do you discuss combination therapy with your high-risk EGFR-mutated locally advanced/metastatic patients?
• How has your practice adapted given recent data?

Recent Videos